# US 2008/0188502 A1 · New Compounds I

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188502 A1
- Document ID: US20080188502A1
- Status: Published application
- Kind: A1
- Application number: 11/769,102
- Filed: 2007-06-27
- Published: 2008-08-07
- Earliest claimed: 2006-06-27
- Assignees: AstraZeneca AB
- Inventors: Jeremy Burrows; Fernando Huerta; Fredrik Lake; Torben Pedersen; Didier Rotticci; Tobias Rein; Karin Staaf; Ulrika Yngve
- Web page: https://patentgrep.com/patent/US20080188502A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/14: for baldness or alopecia
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of formula (I): as a free base or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical formulations containing said compound and to the use of said compound in therapy. The present invention further relates to a process for the preparation of compound of formula (I) and to new intermediates used therein.

## Claims

### Claim at position 1

1-77. (canceled)

### Claim 78

A compound of formula (I):
wherein:
R1 is selected from sulphamoyl, carbamoyl, a group —R5-R6 and a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom; wherein said ring is optionally substituted on carbon by one or more R7; and wherein if said ring contains an additional nitrogen atom that nitrogen is optionally substituted by R8;
at least one of X1, X2, X3 and X4 is selected from N, the other three X1, X2, X3 or X4 are independently selected from N or C(R9), provided that not more than two of X1, X2, X3 or X4 are selected from N;
R2 is halo or cyano;
R3 is methyl, 3-tetrahydropyranyl or 4-tetrahydropyranyl, wherein the tetrahydropyranyl group is optionally substituted on carbon by one or more R10;
R4 is selected from hydrogen, halo, cyano and C1-3alkyl, wherein C1-3alkyl is optionally substituted with one or more halo;
R5 is selected from —O—, —C(O)—, —C(O)O—, —C(O)N(R11)—, —S(O)r, and —SO2N(R12)—; wherein R11 and R12 are independently selected from hydrogen or C1-6alkyl and said alkyl is optionally substituted by one or more R13; and r is 0, 1 or 2;
R6 is selected from C1-6alkyl, carbocyclyl and heterocyclyl; wherein R6 is optionally substituted on carbon by one or more R14; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen is optionally substituted by a group selected from R15;
R7 is selected from halo, cyano, hydroxy, trifluoromethoxy, C1-3alkoxy and C1-3alkyl, wherein said C1-3alkyl is optionally substituted by one or more halo;
R9 is selected from hydrogen, halo, cyano, hydroxy, amino, C1-3alkyl and C1-3alkoxy;
R10, R13 and R14 are independently selected from halo, cyano, hydroxy, amino, sulphamoyl, C1-16alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkoxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC1-3alkyl-R16—, heterocyclylC1-3alkyl-R17—, carbocyclyl-R18— and heterocyclyl-R19—; wherein R10, R13 and R14 are independently of each other substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen is optionally substituted by a group selected from R21;
R16, R17, R18 and R19 are independently selected from —O—, —N(R22)—, —C(O)—, —N(R23)C(O)—, —C(O)N(R24)—, —S(O)s—, —SO2N(R25)— and —N(R26)SO2—; wherein R22, R23, R24, R25 and R26 are independently selected from hydrogen and C1-6alkyl; and s is 0, 1 or 2;
R8, R15 and R21 are independently selected from C1-4alkyl, carbocyclyl, heterocyclyl, —C1-4alkylcarbocyclyl, —C1-4alkylheterocyclyl, C1-4alkanoyl, C1-4alkylsulphonyl and C1-4alkoxycarbonyl; wherein R8, R15 and R21 independently of each other may be optionally substituted on carbon by one or more R27; and
R20 and R27 are independently selected from halo, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, methyl, ethyl, phenyl, cyclopropyl, cyclobutyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, mesyl, ethylsulphonyl and phenyl;
as a free base or a pharmaceutically acceptable salt thereof.

### Claim 79 (depends on 78)

A compound according to claim 78, wherein
R1 is a group —R5-R6 or a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom; wherein said ring may be optionally substituted on carbon by one or more R7; and wherein if said ring contains an additional nitrogen atom that nitrogen is optionally substituted by R8;
at least one of X1, X2, X3 and X4 is selected from N, the other three X1, X2, X3 or X4 are independently selected from N or C(R9) provided that not more than two of X1, X2, X3 or X4 are selected from N;
R2 is halo or cyano;
R3 is methyl or 4-tetrahydropyranyl, wherein said tetrahydropyranyl group is optionally substituted on carbon by one or more R10;
R4 is selected from hydrogen, halo, cyano and C1-3alkyl, wherein said C1-3alkyl is optionally substituted with one or more halo;
R5 is selected from —O—, —C(O)—, —C(O)O—, —C(O)N(R11)—, —S(O)r— and —SO2N(R12)—; wherein R11 and R12 are independently selected from hydrogen or C1-6alkyl and said alkyl is optionally substituted by one or more R13; and r is 0 or 2;
R6 is selected from C1-6alkyl, carbocyclyl and heterocyclyl; wherein R6 is optionally substituted on carbon by one or more R4; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen is optionally substituted by a group selected from R15;
R7 is selected from halo, cyano, hydroxy, trifluoromethoxy, C1-3alkoxy and C1-3alkyl, wherein said C1-3alkyl is optionally substituted by one or more halo;
R9 is selected from hydrogen, halo, cyano, hydroxy, C1-3alkyl and C1-3alkoxy;
R10, R13 and R14 are independently selected from halo, cyano, hydroxy, amino, sulphamoyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkoxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, N—(C1-6alkyl)sulphamoyl, N,N—C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC1-3alkyl-R16—, heterocyclylC1-3alkyl-R17—, carbocyclyl-R18— and heterocyclyl-R19—; wherein R10, R13 and R14 independently of each other are optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen is optionally substituted by a group selected from R21;
R16, R17, R18 and R19 are independently selected from —O—, —N(R22)—, —C(O)—, —N(R23)C(O)—, —C(O)N(R24)—, —S(O)s—, —SO2N(R25)— and —N(R26)SO2—; wherein R22, R23, R24, R25 and R26 are independently selected from hydrogen or C1-6alkyl; and s is 0, 1 or 2;
R8, R15 and R21 are independently selected from C1-4alkyl, carbocyclyl, heterocyclyl, —C1-4alkylcarbocyclyl, —C1-4alkylheterocyclyl, C1-4alkanoyl, C1-4alkylsulphonyl and C1-4alkoxycarbonyl; wherein R8, R15 and R21 independently of each other may be optionally substituted on carbon by one or more R27; and
R20 and R27 are independently selected from halo, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, methyl, ethyl, phenyl, cyclopropyl, cyclobutyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, mesyl and ethylsulphonyl; as a free base or a pharmaceutically acceptable salt, an in vivo hydrolysable ester, solvate or solvate of a salt thereof.

### Claim 80 (depends on 78, 79)

A compound according to claim 78 or 79, wherein R2 is halo.

### Claim 81 (depends on 78, 79)

A compound according to claim 78 or 79, wherein R2 is fluoro.

### Claim 82 (depends on 78, 79)

A compound according to claim 78 or 79, wherein R3 is 4-tetrahydropyranyl or methyl.

### Claim 83 (depends on 78, 79)

A compound according to claim 78 or 79, wherein R4 is hydrogen or C1-3alkyl, wherein said C1-3alkyl is optionally substituted with one or more halo.

### Claim 84 (depends on 83)

A compound according to claim 83, wherein R4 is C1-3alkyl.

### Claim 85 (depends on 84)

A compound according to claim 84, wherein R4 is methyl.

### Claim 86 (depends on 83)

A compound according to claim 83, wherein R4 is trifluoromethyl.

### Claim 87 (depends on 78, 79)

A compound according to claim 78 or 79, wherein R5 is —C(O)— or —S(O)r—; and r is 0 or 2.

### Claim 88 (depends on 87)

A compound according to claim 87, wherein R5 is —C(O)—.

### Claim 89 (depends on 87)

A compound according to claim 87, wherein R5 is —S(O)r—; and r is 2.

### Claim 90 (depends on 78, 79)

A compound according to claim 78 or 79, wherein R5 is —O— or C(O)O—.

### Claim 91 (depends on 78, 79)

A compound according to claim 78 or 79, wherein R5 is —C(O)N(R11)— or —SO2N(R12)—; wherein R11 and R12 are independently selected from hydrogen or C1-6alkyl.

### Claim 92 (depends on 78, 79)

A compound according to claim 78 or 79, wherein R6 is C1-6alkyl or heterocyclyl; wherein R6 is optionally substituted on carbon by one or more R14; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen is optionally substituted by a group selected from R15.

### Claim 93 (depends on 92)

A compound according to claim 92, wherein said C1-6alkyl is methyl, ethyl, butan-2-yl, butan-3-yl, propan-2-yl or tert-butyl.

### Claim 94 (depends on 92)

A compound according to claim 92, wherein said heterocyclyl is selected from morpholinyl, homomorpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, homopiperidinyl and homopiperazinyl.

### Claim 95 (depends on 94)

A compound according to claim 94, wherein said heterocyclyl is selected from piperidinyl, pyrrolidinyl, azetidinyl and piperazinyl.

### Claim 96 (depends on 92)

A compound according to claim 92, wherein R14 is C1-6alkoxy, halo, C1-6alkyl, carbocyclyl, heterocyclyl and N,N—(C1-6alkyl)2amino; wherein R14 is optionally substituted on carbon by one or more R20.

### Claim 97 (depends on 92)

A compound according to claim 92, wherein R15 is C1-4alkyl or carbocycle; wherein R15 is optionally substituted on carbon by one or more R27.

### Claim 98 (depends on 78, 79)

A compound according to claim 78 or claim 79, wherein R8 is C1-4alkyl, and wherein R8 may be optionally substituted on carbon by one or more R27.

### Claim 99 (depends on 97, 98)

A compound according to claim 97 or claim 98, wherein R27 is hydroxy, halo, ethoxy, methoxy or phenyl.

### Claim 100 (depends on 98)

A compound according to claim 98, wherein R27 is hydroxy, halo, ethoxy, methoxy or phenyl.

### Claim 101 (depends on 78, 79)

A compound according to claim 78 or claim 79, wherein at least one of X2, X3 and X4 is selected from N, the other two X2, X3 or X4 are independently selected from N or C(R9).

### Claim 102 (depends on 101)

A compound according to claim 101, wherein X3 or X4 is N.

### Claim 103 (depends on 78, 79)

A compound according to claim 78 or claim 79, wherein R9 is hydrogen, methyl, trifluoromethyl, trifluoromethoxy or halo.

### Claim 104 (depends on 103)

A compound according to claim 103, wherein R9 is hydrogen.

### Claim 105 (depends on 103)

A compound according to claim 103, wherein one of R9 is halo.

### Claim 106 (depends on 105)

A compound according to claim 105, wherein said halo is chloro.

### Claim 107 (depends on 78, 79)

A compound according to claim 78 or claim 79, wherein
R1 is a group —R5-R6;
at least one of X1, X2, X3 and X4 is selected from N, the other three X1, X2, X3 or X4 are independently selected from N or C(R9), provided that not more than two of X1, X2, X3 or X4 are selected from N;
R2 is halo;
R3 is methyl or 4-tetrahydropyranyl;
R4 is C1-3alkyl, wherein said C1-3alkyl is optionally substituted with one or more halo;
R5 is selected from —O—, —C(O)—, —C(O)O—, —C(O)N(R11)—, —S(O)r— and —SO2N(R12)—; wherein
R11 and R12 are independently selected from hydrogen or C1-6alkyl and said alkyl is optionally substituted by one or more R13 and r is 2;
R6 is C1-6alkyl or heterocyclyl; wherein R6 is optionally substituted on carbon by one or more R14; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen is optionally substituted by a group selected from R15;
R9 is hydrogen or halo;
R14 is selected from halo, C1-6alkyl, carbocycle, N,N—(C1-6alkyl)2amino, heterocyclyl and C1-6alkoxy; wherein R14 is optionally on carbon by one or more R20;
R15 is C1-4alkyl or carbocycle; wherein R15 is optionally substituted on carbon by one or more R27; and
R20 and R27 are independently selected from halo, methoxy, ethoxy, and phenyl.

### Claim 108 (depends on 78, 79)

A compound according to claim 78 or 79, wherein,
R1 is a group —R5-R6;
at least one of X1, X2, X3 and X4 is selected from N, the other three X1, X2, X3 or X4 are independently selected from N or C(R9), provided that not more than two of X1, X2, X3 or X4 are selected from N;
R2 is halo;
R3 is 4-tetrahydropyranyl;
R4 is C1-3alkyl;
R5 is —C(O) or —S(O)r— and —SO2N(R12)—; and r is 2;
R6 is C1-6alkyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen is optionally substituted by a group selected from R15;
R9 is hydrogen; and
R15 is C1-4alkyl.

### Claim 109 (depends on 78, 79)

A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of a compound according to in claim 78 or claim 79 in association with pharmaceutically acceptable excipients, carriers or diluents.

### Claim 110 (depends on 78, 79)

A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 111 (depends on 78, 79)

A method of prevention and/or treatment of cognitive disorders, comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 112 (depends on 111)

The method according to claim 111, wherein the cognitive disorder is dementia, Cognitive Deficit in Schizophrenia (CDS), Mild Cognitive Impairment (MCI), Age-Associated Memory Impairment (AAMI), Age-Related Cognitive Decline (ARCD) or Cognitive Impairment No Dementia (CIND).

### Claim 113 (depends on 112)

The method according to claim 112, wherein the disease is Cognitive Deficit in Schizophrenia.

### Claim 114 (depends on 112)

The method according to claim 112, wherein the dementia is associated with neurofibrillar tangle pathologies.

### Claim 115 (depends on 112)

The method according to claim 112, wherein the dementia is Frontotemporal dementia (FTD), Frontotemporal dementia Parkinson's Type (FTDP), progressive supranuclear palsy (PSP), Pick's Disease, Niemann-Pick's Disease, corticobasal degeneration, traumatic brain injury (TBI) or dementia pugilistica.

### Claim 116 (depends on 115)

The method according to claim 115, wherein the dementia is Alzheimer's Disease (AD), Down syndrome, vascular dementia, Parkinson's Disease (PD), postencephelatic parkinsonism, dementia with Lewy bodies, HIV dementia, Huntington's Disease, amyotrophic lateral sclerosis (ALS), motor neuron diseases (MND), Creuztfeld-Jacob's disease or prion diseases.

### Claim 117 (depends on 116)

The method according to claim 116, wherein the dementia is Alzheimer's Disease.

### Claim 118 (depends on 116)

The method according to claim 116, wherein the treatment is in the delay of the disease progression of Alzheimer's Disease.

### Claim 119 (depends on 78, 79)

A method of prevention and/or treatment of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) or affective disorders, comprising administering to a human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 120 (depends on 119)

The method according to claim 119, wherein the affective disorders are Bipolar Disorder including acute mania, bipolar depression, bipolar maintenance, major depressive disorders (MDD) including depression, major depression, mood stabilization, schizoaffective disorders including schizophrenia, or dysthymia.

### Claim 121 (depends on 78, 79)

A method of prevention and/or treatment of Type I diabetes, Type II diabetes, diabetic neuropathy, alopecia, inflammatory diseases or cancer, comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a salt compound as defined in claim 78 or claim 79.

### Claim 122 (depends on 78, 79)

A method of prevention and/or treatment of bone related disorders or conditions comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a salt compound as defined in claim 78 or claim 79.

### Claim 123 (depends on 78, 79)

A method of prevention and/or treatment of osteoporosis comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 124 (depends on 78, 79)

A method of increasing bone formation comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 125 (depends on 78, 79)

A method of increasing cancellous bone formation and/or new bone formation comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 126 (depends on 78, 79)

A method of increasing bone mineral density comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 127 (depends on 78, 79)

A method of reducing the incidence of fracture comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 128 (depends on 78, 79)

A method of enhancing fracture healing comprising administering to a human in need of such prevention and/or treatment a therapeutically effective amount of a compound as defined in claim 78 or claim 79.

### Claim 129 (depends on 78)

A process for preparing a compound of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, which process comprises:
a) reacting a pyrimidine of formula (II):
with a compound of formula (III):
wherein
Y is a displaceable group; and
R1, R2, R3, R4, X1, X2, X3 and X4 are, unless otherwise specified, defined as in claim 78; and thereafter optionally:
b) converting a compound of the formula (I) into another compound of formula (I);
c) removing any protecting groups; and
d) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.
